



## NOTICE

NOTICE IS HEREBY GIVEN THAT THE FOURTEENTH ANNUAL GENERAL MEETING OF THE MEMBERS OF M/S VILIN BIO MED LIMITED SHALL BE HELD ON THURSDAY, DECEMBER 31, 2020 AT 11:00 A.M. AT THE REGISTERED OFFICE OF THE COMPANY SITUATED AT H. NO. 6-61/1, FIRST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR, HYDERABAD – 500035, TELANGANA, INDIA

---

### Ordinary Business:

1. To receive, consider and adopt the Audited Financial Statements for the Financial Year 2019-2020 together with the Reports of Directors and Auditor's thereon:

To consider and, if thought fit, to pass with or without modifications, the following Resolution as an Ordinary Resolution:

**"RESOLVED THAT** the Audited Financial Statements for the Financial Year ended March 31, 2020 containing the Audited Balance Sheet as at March 31, 2020, the Statement of Profit and Loss Account for the period ended on that date, the Cash Flow Statement and Notes to Accounts together with the Report of the Directors and Auditor's thereon be and are hereby approved and adopted."

**"RESOLVED FURTHER THAT** the Directors of the Company, be and are hereby severally authorised to do all such acts, things and deeds including but not limited to filing of requisite Forms / Returns with the office of the Registrar of Companies so as to bring this Resolution in to force."

### Special Business

2. Regularization of Mr. Anvesh Moola (DIN: 08659891) as Director of the Company:

To consider and, if thought fit, to pass with or without modifications, the following Resolution as an Ordinary Resolution:

**"RESOLVED THAT** pursuant to the provisions of Sections 152, 160 and other applicable provisions, if any, of the Companies Act, 2013 ('the Act') read with the Companies (Appointment and Qualifications of Directors) Rules, 2014, as amended from time to time, and pursuant to the recommendation of the Board of Directors, Mr. Anvesh Moola (DIN: 08659891), Additional Director of the Company, be and is hereby appointed as Director of the Company liable to retire by rotation."

**"RESOLVED FURTHER THAT** the Directors of the Company, be and are hereby severally authorised to do all such acts, things and deeds including but not limited to filing of requisite Forms / Returns with the office of the Registrar of Companies so as to bring this Resolution in to force."



# VILIN BIO MED LTD.

Unit-II, Khasra No. 85, Madhopur Village, Hazaratpur, Roorkee, Dist : Haridwar (Uttarakhand)  
E-mail : vilinbiomedltd@yahoo.co.in

### 3. Regularization of Mr. Ashok Kumar Beniwal (DIN: 08659902) as Director of the Company:

To consider and, if thought fit, to pass with or without modifications, the following Resolution as an Ordinary Resolution:

"**RESOLVED THAT** pursuant to the provisions of Sections 152, 160 and other applicable provisions, if any, of the Companies Act, 2013 ('the Act') read with the Companies (Appointment and Qualifications of Directors) Rules, 2014, as amended from time to time, and pursuant to the recommendation of the Board of Directors, Mr. Ashok Kumar Beniwal (DIN: 08659902), Additional Director of the Company, be and is hereby appointed as Director of the Company."

"**RESOLVED FURTHER THAT** the Directors of the Company, be and are hereby severally authorised to do all such acts, things and deeds including but not limited to filing of requisite Forms / Returns with the office of the Registrar of Companies so as to bring this Resolution in to force."

By the Order of Board  
For Vilin Bio Med Limited



Date: December 26, 2020  
Place: Hyderabad

Addagunta Venu Gopal  
Director  
DIN: 01918868



# VILIN BIO MED LTD.

Unit-II, Khasra No. 85, Madhopur Village, Hazaratpur, Roorkee, Dist : Haridwar (Uttarakhand)  
E-mail : vilinbiomedltd@yahoo.co.in

---

## NOTES:

1. A MEMBER ENTITLED TO ATTEND AND TO VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON A POLL INSTEAD OF HIMSELF AND SUCH A PROXY NEED NOT BE A MEMBER OF THE COMPANY.
2. PROXY(IES) IN ORDER TO BE EFFECTIVE MUST BE RECEIVED AT THE COMPANY'S REGISTERED OFFICE NOT LESS THAN 48 HOURS BEFORE THE COMMENCEMENT OF THE MEETING.
3. THE FOURTEENTH ANNUAL GENERAL MEETING OF THE COMPANY IS BEING HELD ON DECEMBER 31, 2020 IN ACCORDANCE WITH THE GENERAL ORDER: ROCH/STA/2020-21 DATED SEPTEMBER 8, 2020 ISSUED BY THE REGISTRAR OF COMPANIES, HYDERABAD GRANTING EXTENSION OF THE TIME FOR HOLDING THE ANNUAL GENERAL MEETING UNDER SECTION 96(1) OF THE COMPANIES ACT, 2013 FOR THE FINANCIAL YEAR 2019-2020 UP TO DECEMBER 31, 2020.



# VILIN BIO MED LTD.

Unit-II, Khasra No. 85, Madhopur Village, Hazaratpur, Roorkee, Dist : Haridwar (Uttarakhand)  
E-mail : vilinbiomedltd@yahoo.co.in

## **Explanatory Statement**

(Pursuant to Section 102 of Companies Act, 2013)

### **Item No. 2**

Mr. Anvesh Moola (DIN: 08659891) was appointed as Additional Director in accordance with the provisions of Section 161 of the Companies Act, 2013 and the said Director holds office up to the date of ensuing Annual General Meeting of the Company. The Company has received notice from a Shareholder under Section 160 of the Companies Act, 2013 proposing the appointment of Mr. Anvesh Moola as Director of the Company. Further, the Board is of the view that the appointment of Mr. Anvesh Moola, on the Company Board is desirable and would be beneficial to the Company and hence it recommends the said Resolution No. 2 for approval by the Members of the Company.

None of the Directors of the Company are in any way concerned or interested, in the said Resolution except Mr. Anvesh Moola, is concerned in the said Resolution. The Board recommends the said Resolution to be passed as an Ordinary Resolution.

### **Item No. 3**

Mr. Ashok Kumar Beniwal (DIN: 08659902) was appointed as Additional Director in accordance with the provisions of Section 161 of the Companies Act, 2013 and the said Director holds office up to the date of ensuing Annual General Meeting of the Company. The Company has received notice from a Shareholder under Section 160 of the Companies Act, 2013 proposing the appointment of Mr. Ashok Kumar Beniwal as Director of the Company. The Board is of the view that his appointment would be beneficial to the Company. Hence it recommends passing the Resolutions as set out in item No. 3 and 4 for approval by the Members of the Company.

Except Mr. Ashok Kumar Beniwal, None of the Directors of the Company is interested in the said Resolutions.

By the Order of Board  
For Vilin Bio Med Limited

Date: December 26, 2020

Place: Hyderabad

Addagunta Venu Gopal

Director

DIN: 01918868

VILIN BIO MED LIMITED

CIN: U24230TG2005PLC046689

Address: H.NO.6-61-1,1ST FLOOR, SHILPI COMPLEX,

DILSUKHNAGAR HYDERABAD TG 500035 IN

Email Id: vilinbiomedltd@yahoo.co.in

### **Director's Report**

To

**The Members**

**Your Directors take pleasure in presenting the Director's Report on the business and operations of your Company along with the Audited Statements of Accounts for the year ended 31 March, 2020.**

#### **1. Financial Summary or Highlights / Performance of the Company (Standalone)**

The Board's Report has been prepared based on the Standalone Financial Statements of the Company.

<b>PARTICULARS</b>	<b>CURRENT YEAR (2019-20) (Amount in Rs.)</b>	<b>PREVIOUS YEAR (2018-19) (Amount in Rs.)</b>
Turnover & Other Income	16,82,41,474.19	18,92,40,716.17
Less: Expenditure	16,31,86,857.99	18,34,90,443.30
Profit/(Loss) Before Depreciation	50,54,616.20	57,50,272.87
Less: Depreciation	31,16,340.17	36,32,483.00
Profit/(Loss) After Depreciation	19,38,276.03	21,17,789.87
Less: Net Current Tax	5,00,000.00	5,50,000.00
Less: Previous Year Tax	(1,38,337.00)	(50,000.00)
Less: Deferred Tax Liability /(Assets)	-	-
Profit/Loss After Tax	15,76,613.03	15,17,789.87

#### **2. Details of Subsidiary/Joint Ventures/Associate Companies**

Company does not have any Subsidiary Company/ Joint Venture/ Associate Company during the Financial Year.

#### **3. Performance and Financial Position of each of the Subsidiaries, Associates and Joint Venture Companies included in the Financial Statement**

Since the Company does not have any Subsidiary, Associate or Joint Venture Company, the requirement to provide the Performance and Financial Position of each of the Subsidiaries, Associates and Joint Venture Companies does not arise.

#### **4. Dividend**

In view of the planned business growth, your Directors deem it proper to preserve the resources of the Company for its activities and therefore, do not propose any Dividend for the Financial Year ended March 31, 2020.

#### **5. Reserves**

The Company proposes to transfer a sum of Rs.15,76,613.04/- to Surplus during the Financial Year ended March 31, 2020.

#### **6. Statement on Company's Affairs**

During the Financial Year under review, the Company has earned Profit of Rs.15,76,613.04/- for the Financial Year ended March 31, 2020 and the Directors have been making continuous efforts to increase the profitability of the Company and targets to achieve much better results in the years to come.

#### **7. Change in the nature of the business, if any**

There is no change in the nature of business of the Company.

#### **8. Material changes and commitments, if any, affecting the Financial Position of the Company which have occurred between the end of the Financial Year 2019-2020 (i.e. from 1st day of April 2019) of the Company to which the Financial Statements relate and till the date of this Report.**

There has been no material changes and commitments affecting Financial Position of the Company that have occurred between the Balance Sheet Date and date of this Report.

#### **9. Detail of Significant and Material Orders passed by the Regulators or Courts or Tribunals impacting the Going Concern Status and Company's operations in future**

No such significant and material order has been passed by any Regulators or Courts or Tribunals impacting the Going Concern Status and Company's operations in future.

#### **10. Deposits**

During the year under review, the Company has not accepted any Deposits in terms of Sections 73 and 74 of the Companies Act, 2013 read together with the Companies (Acceptance of Deposits) Rules, 2014. The Company did not have Outstanding Deposits at the beginning / at the end of the year.

#### **11. Explanation or comments on Qualifications, Reservations or Adverse Remarks or disclaimers made by the Auditors and/or the Practicing Company Secretary in their Reports**

##### **A. Auditor's Report:**

The Notes on financial statement referred to in the Auditors' Report are self-explanatory and do not call for any further comments. The Auditors' Report does not contain any comments, Qualification, Reservation or Adverse Remark.

## **B. Secretarial Auditor's Report:**

The Provisions of Section 204 of Companies act, 2013 relating to Secretarial Audit are not applicable for your Company so no Reports are required to receive from the Practicing Company Secretary.

## **12. Financial Position**

### **A) Issue of Equity Shares with Differential Voting Rights**

No Equity Shares with Differential Voting Rights has been issued by the Company during the Financial Year.

### **B) Issue of Sweat Equity Shares**

The Company has not issued Sweat Equity Shares pursuant to provisions of Section 54 read with Rule 8 of the Companies (Share Capital and Debenture) Rules, 2014 during the Financial Year.

### **C) Issue of Employee Stock Options**

The Company does not have issued shares under employee's stock options scheme pursuant to provisions of Rule 12(9) of the Companies (Share Capital and Debenture) Rules, 2014, so question does not arise about Voting Rights not exercised by employee during the year under review.

### **D) Buy Back of Securities**

The Company has not bought-back any of its Securities pursuant to the provision of Section 67 and Section 68 of the Companies Act, 2013 during the year under review.

## **13. Corporate Social Responsibility (CSR)**

Provisions of Corporate Social Responsibility pursuant to the provisions of the Section 135 of the Companies Act 2013 is not applicable to your Company.

## **14. Directors**

### **A) Changes in Directors and Key Managerial Personnel**

The details about the changes in the Directors or Key Managerial Personnel by way of Appointment, re-designation, Resignation, Death or Disqualification, variation made or withdrawn etc., are as follow:

<b>NAME OF DIRECTORS</b>	<b>CHANGE IN DESIGNATION, APPOINTMENT, REGULARIZATION, RETIREMENT, RESIGNATION</b>	<b>DATE OF SUCH EVENT</b>
Anvesh Moola	Appointment	06.01.2020
Ashok Kumar Beniwal	Appointment	06.01.2020

Merugu Ramesh	Resignation	07.01.2020
Akkireddy Pradeep Reddy	Resignation	07.01.2020
Krishna Reddy Roppireddy	Resignation	07.01.2020

**B) Declaration by an Independent Director(s) and re-appointment, if any**

Provisions of Independent Director is not applicable to our Company.

**C) Formal Annual Evaluation**

Provision of Clause-P of Section 134(3) of the Companies Act, 2013 regarding performance evaluation of Director, is not applicable to our Company.

**15. Number of Board Meetings of Board of Directors**

The Board of Directors duly met seven times during the year for which proper notices were given and the proceedings were properly recorded in the Minutes Book maintained for the purpose.

Serial No.	Date of Board Meeting	Number of Directors who attended the Board Meeting
01	15.05.2019	4
02	14.06.2019	4
03	06.07.2019	4
04	17.09.2019	4
05	06.01.2020	4
06	07.01.2020	3
07	18.03.2020	3

**16. Audit Committee**

Provision of Audit Committee is not applicable to our Company.

**17. Details of establishment of Vigil Mechanism for Directors and Employees**

Provision of Vigil Mechanism is not applicable to our Company.

## **18. Nomination and Remuneration Committee**

Provision of Nomination and Remuneration Committee is not applicable to our Company.

## **19. Particulars of Loans, Guarantees or Investments under Section 186**

During the Financial Year 2019-20, the Company did not grant any Loan or provide any Guarantee or made any Investment in Securities as per the provisions of Section 186 of the Companies Act, 2013.

## **20. Particulars of Contracts or Arrangements with Related Parties**

In Financial Year 2019-20, Company has not entered into any Contracts or Arrangements with Related Parties.

## **21. Risk Management Policy**

In Addition to risk that already exists, the Management is assimilating the Risk Management Policy.

## **22. Directors Responsibility Statement**

The Directors Responsibility Statement referred to in (c) of Sub-Section (3) of Section 134 of the Companies Act, 2013, state that:

(a) in the preparation of the Annual Accounts, the applicable Accounting Standards had been followed along with proper explanation relating to material departures;

(b) the Directors had selected such Accounting Policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the State of Affairs of the Company at the end of the Financial Year and of the Profit and Loss of the Company for that period;

(c) the Directors had taken proper and sufficient care for the maintenance of adequate Accounting Records in accordance with the provisions of this Act for safeguarding the Assets of the Company and for preventing and detecting fraud and other irregularities;

(d) the Directors had prepared the Annual Accounts on a Going Concern Basis; and

(e) the Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

## **23. Compliance with the provision of Secretarial Standard-1 and Secretarial Standard -2:**

The applicable provisions of Secretarial Standards SS-1 and SS - 2 relating to 'Meeting of Board of Directors' and 'General Meeting' respectively has been duly complied by your Company.

## **24. Disclosure about Cost Audit**

Provision given under Section 148 of Companies Act,2013 and Rule 14 of Company (Auditand Auditor) Rules, 2014 is not applicable to our Company.

## **25. Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo**

The disclosure to be made under Sub-Section (3) (m) of Section 134 of the Companies Act 2013 read with Rule (8) (3) of the Companies (Accounts) Rules, 2014 by your Company are explained as under:

a) **Conservation of Energy & Technology Absorption:** As the Company is engaged in manufacturing activity, it has taken positive steps for conservation of Energy & Technology absorption.

b) **Foreign Exchange Earning & Outgo:** There was no Foreign Exchange Earnings & Outgo during the year.

## **26. Internal Financial Controls**

The Board of your Company has laid down Internal Financial Controls to be followed by the Company and that such Internal Financial Controls are adequate and operating effectively.

## **27. Details of amount received from Directors or Relative of Directors pursuant to Companies (Acceptance of Deposits) Rules, 2014.**

During the Financial Year 2019-20, No amount was received from Directors or Relatives of Directors pursuant to provisions of Companies (Acceptance of Deposits) Rules, 2014.

## **28. Anti-Sexual Harassment Policy**

The Company has in place an Anti-Sexual Harassment Policy in line with the requirements of Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act 2013. All employees including trainees are covered under this Policy.

The following is the summary of Sexual Harassment Complaints received and disposed off during the current Financial Year.

Number of Complaints received: Nil

Number of Complaints disposed off: Nil

## **29. Details of each of the fraud reported to the Audit Committee or the Board by Statutory Auditor, Cost Auditor or Secretarial Auditor:**

There was no fraud reported in the Company during the Financial Year ended March 31, 2020. This is also being supported by the Report of the Auditors of the Company as no fraud has been reported in their Audit Report for the Financial Year ended March 31, 2020.

## **30. Maintenance of Cost Records as specified by the Central Government under Sub-Section (1) of Section 148 of the Companies Act, 2013, is required by the Company and accordingly such Accounts and Records are made and maintained**


The Company is not required to make or maintain the Cost Records under Section 148(1) of the Companies Act, 2013.

### **31. Acknowledgements**

An acknowledgement to all with whose help, co-operation and hard work the Company is able to achieve the results.

*For and on behalf of the Board of Directors*

**VILIN BIO MED LIMITED**



**(Director)**

**Name: Addagunta Venu Gopal**

**DIN: 01918868**

**R/o: 12-5-14/20, Flat No-T-3,**

**Gouthaminagar**

**Mancherial, Adilabad**

**Telangana - 504208**

**India**



**Sd/-  
(Director)**

**Name: Anvesh Moola**

**DIN: 08659891**

**R/o: 3-9-55/3, Reddy Colony**

**Hanamkonda, D H Suthoon**

**Warangal, Hanamkonda**

**Telangana - 506011**

**India**

**Place: Roorkee**

**Date: 26-12-2020**



# Singh Yudhveer & Associates

## Chartered Accountants

### INDEPENDENT AUDITORS' REPORT

#### TO THE MEMBERS OF M/S VILIN BIOMED LIMITED

#### Report on the Financial Statements

We have audited the accompanying financial statements of **M/S VILIN BIOMED LIMITED** ("the company"), which comprise the Balance Sheet as at 31 March 2020, the Statement of Profit and Loss, the Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

#### Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation and presentation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes the maintenance of adequate accounting records in accordance with the provision of the Act for safeguarding of the assets of the Company and for preventing and detecting the frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial control, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

#### Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give true and fair view, in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and operating effectiveness of such controls. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

#### Opinion

In our opinion and to the best of our information and according to the explanations given to us, the financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the state of affairs of the Company as at 31st March 2020, its profit/loss and its cash flows for the year ended on that date.



### Report on other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure-A a statement on the matters Specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by section 143(3) of the Act, we report that:
  - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - b) In our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
  - c) the Balance Sheet, the Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account.
  - d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
  - e) On the basis of written representations received from the directors as on 31 March 2020, taken on record by the Board of Directors, none of the directors is disqualified as on 31 March, 2020, from being appointed as a director in terms of Section 164(2) of the Act.
  - f) With respect to the adequacy of the Internal financial controls over financial reporting of the company and the operating effectiveness of such controls, refer to our separate Report in Annexure-B.
  - g) In our opinion and to the best of our information and according to the explanations given to us, we report as under with respect to other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014:
    - i. The Company does not have any pending litigations which would impact its financial position.
    - ii. The Company did not have any long-term contracts including derivatives contracts for which there were any material foreseeable losses.
    - iii. There were no amounts which required to be transferred by the Company to the Investor Education and Protection Fund.

For SINGH YUDHVEER & ASSOCIATES  
Chartered Accountants  
(Firm Registration No.: 011039C)

  
YUDHVEER SINGH  
Proprietor  
(Membership No.: 401054)



Place: Roorkee  
Date: 26-12-2020

**UDIN:-2401054AAAABJ9116**

**ANNEXURE-A TO THE INDEPENDENT AUDITOR'S REPORT**

(Referred to in paragraph 1 under 'Report on the Other Legal and Regulatory Requirements' of our report of even date attached)

**Report on Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government in terms of Section 143(11) of the Companies Act, 2013 ("the Act") of VILIN BIO-MED LIMITED ("the Company).**

1. In respect of the Company's Fixed Assets:
  - (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
  - (b) The fixed assets were physically verified during the year by the Management in accordance with a regular program of verification which, in our opinion, provides for physical verification of all the fixed assets at reasonable intervals. According to the information and explanations given to us, no material discrepancies were noticed on such verification.
  - (c) According to the information and explanations given to us and the records examined by us and based on the examination of the conveyance deed provide to us, we report that, the title deeds, comprising all the immovable properties of land and buildings which are freehold, are held in the name of the Company as at the balance sheet date.
2. As explained to us, the inventories were physically verified during the year by the Management at reasonable intervals and no material discrepancies were noticed on physical verification.
3. The Company has not granted any loans, secured or unsecured, to companies, firms, limited liability partnerships of other parties covered in the register maintained under Section 189 of the Act.
4. In our opinion and according to the information and explanation given to us, the Company has complied with the provision of Sections 185 and 186 of the Act in respect of grant of loans, making investments and providing guarantees and securities, as applicable.
5. The Company has not accepted deposits during the year and does not have any unclaimed deposits as at March 31, 2020 and therefore, the provisions of clause 3 (v) of the Order are not applicable to the Company.
6. As informed to us, the Central Government has not prescribed maintenance of cost records under sub-section (1) of Section 148 of the Act, in respect of the activities carried on by the Company.
7. According to the information and explanations given to us, in respects of statutory dues:
  - (a) The Company has generally been regular in depositing undisputed statutory dues, including Provident Fund, Employees State Insurance, Income Tax, Sales Tax, Service Tax, Value Added Tax, Duty of Customs, Duty of Excised, Cess and other material statutory dues applicable to it with the appropriate authority.
  - (b) According to the information and explanations given to us, no undisputed amounts payable in respect of Income-tax, Wealth Tax, Custom Duty, Excise Duty, sales tax, VAT, Cess and other material statutory dues in arrears /were outstanding as at 31 March, 2020 for a period of more than six months from the date they became payable except. A sum of Rs. 31.70 lakhs Income tax payable for A.Y.-2012-13, A.Y. 2013-14 & A.Y. 2015-16, A.Y. 2017-18.
  - (c) According to the information and explanations given to us, there has not been an occasion in case of the Company during the year under report to transfer any sum to the Investor Education and Protection Fund. The question of reporting delay in transferring such sums does not arise as at 31st March 2020, the Company has been registered for less than 5 years: hence, clause 3(vii) (C) of the Order is not applicable.
8. In our opinion and according to the information and explanations given to us, the Company has not defaulted in the repayment of loans or borrowing to banks. The Company does not have any loans or borrowing from the financial institutions or government and has not issued any debentures.



9. The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) or term loans and hence reporting under clause 3(ix) of the Order is not applicable.
10. To the best of our knowledge and according to the information and explanations given to us, no fraud by the Company and no fraud on the Company by its officers or employees has been noticed or reported during the year.
11. In our opinion and according to the information and explanations given to us, the Company has paid/provide managerial remuneration in accordance with the requisite approvals mandated by the provisions of Section 197 read with Schedule V to the Act.
12. The Company is not a Nidhi Company and hence reporting under clause 3(xii) of the Order is not applicable.
13. In our opinion and according to the information and explanations given to us the Company is in compliance with Section 177 and 188 of the Act, where applicable, for all transactions with the related parties and the details of related party transaction have been disclosed in the standalone financial statements as required by the applicable accounting standards.
14. During the year, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures and hence reporting under clause 3(xiv) of the Order is not applicable to the Company.
15. In our opinion and according to the information and explanations given to us, during the year the Company has not entered into non-cash transactions with its Directors or persons connected to its Directors and hence provision of Section 192 of the Act is not applicable.
16. The Company is not required to be registered under Section 45-I of the Reserve Bank of India Act, 1934.

For SINGH YUDHVEER & ASSOCIATES  
Chartered Accountants  
(Firm Registration No.: 011039C)

  
YUDHVEER SINGH  
Proprietor  
(Membership No.: 401054)



Place: Roorkee  
Date: 26-12-2020

**UDIN:-2401054AAAABJ9116**

**Annexure-B to the Independent Auditor 's Report of even date on the -Financial Statement of M/S VILIN BIOMED LIMITED**

**Report on the internal financial controls under clause (i) of sub section 3 of section 143 of the Companies Act, 2013 ("the Act")**

We have audited the internal financial controls over financial reporting of M/s Vilin Bio-Med Limited ("the Company") as of March 31, 2020 in conjunction with our audit of the financial Statements of the Company for the year ended on that date.

**Management 's Responsibility for Internal Financial Controls**

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

**Auditor's Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and specified under sub-section 10 of under section 143 of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Control; and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting; assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risk of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtain is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

**Meaning of Internal Financial Controls over Financial Reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorization of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.



### **Inherent Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subjects to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion, the Company has, in all material respect, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2020, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For SINGH YUDHVEER & ASSOCIATES  
Chartered Accountants  
(Firm Registration No.: 011039C)

  
YUDHVEER SINGH  
Proprietor  
(M. No.- 401054)



Place: Roorkee  
Date: 26-12-2020

**UDIN:-2401054AAAABJ9116**

**VILIN BIO-MED LIMITED**  
**REGD. OFF :H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR**  
**HYDERABAD, TELANGANA - 500035**  
**WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667**  
**DISTT - HARIDWAR, UTTARAKHAND**  
**CIN :- U24230TG2005PLC046689**

**BALANCE SHEET AS AT 31st MARCH 2020**

PARTICULARS		NOTE NO.	AS AT 31st MARCH 2020 (IN RS.)	AS AT 31st MARCH 2019 (IN RS.)
<b>I.</b>	<b>EQUITY AND LIABILITIES</b>			
<b>1</b>	<b>Shareholders' funds</b>			
	(a) Share capital	2	33,000,000.00	33,000,000.00
	(b) Reserves and surplus	3	39,368,109.49	37,791,496.40
<b>2</b>	<b>Share application money pending allotment</b>		-	-
<b>3</b>	<b>Non-current liabilities</b>			
	(a) Long-term borrowings	-	-	-
	(b) Deferred tax liabilities (Net)	-	616,158.71	616,158.71
<b>4</b>	<b>Current liabilities</b>			
	(a) Short-term borrowings	4	45,341,186.00	30,271,069.30
	(b) Trade payables	5	18,605,552.25	10,190,916.80
	(c) Other current liabilities	6	2,478,665.00	5,559,477.30
	(d) Short-term provisions	7	650,000.00	697,500.00
	<b>TOTAL</b>		<b>140,059,671.45</b>	<b>118,126,618.60</b>
<b>II.</b>	<b>ASSETS</b>			
	<b>Non-current assets</b>			
<b>1</b>	(a) Fixed assets			
	(i) Tangible Assets	8	21,260,297.60	24,133,722.20
	(b) Long-term loans and advances	9	485,213.00	485,213.00
	(c) Other non-current assets		-	-
<b>2</b>	<b>Current assets</b>			
	(a) Inventories	10	21,095,978.00	20,032,785.90
	(b) Trade receivables	11	72,693,180.08	61,242,840.80
	(c) Cash and cash equivalents	12	666,207.84	395,880.00
	(d) Short-term loans and advances	13	23,858,794.93	11,836,176.70
	<b>TOTAL</b>		<b>140,059,671.45</b>	<b>118,126,618.60</b>

FOR & ON BEHALF OF THE BOARD OF DIRECTOR

AS PER OUR SEPARATE REPORT OF EVEN DATE ATTACHED  
FOR SINGH YUDHVEER & ASSOCIATES  
CHARTERED ACCOUNTANTS

**For Vilin Bio Med Ltd**  
A. VENUGOPAL  
Managing Director

MG. DIRECTOR  
DIN-01918868

PLACE: ROORKEE  
DATE: 26-12-2020

ANVESH MOOLA

DIRECTOR  
DIN-08659891



YUDHVEER SINGH  
PROPRIETOR  
M. NO. 401054


**VILIN BIO-MED LIMITED**  
 REGD. OFF :H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR  
 HYDERABAD, TELANGANA - 500035  
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667  
 DISTT - HARIDWAR, UTTARAKHAND  
 CIN :- U24230TG2005PLC046689


**STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31st MARCH 2020**

PARTICULARS		NOTE NO.	AS AT 31st MARCH 2020 (IN RS.)	AS AT 31st MARCH 2019 (IN RS.)
I.	Revenue from operations	14	168,129,474.19	189,240,716.1
II.	Other income	15	112,000.00	-
III.	<b>Total Revenue (I + II)</b>		<b>168,241,474.19</b>	<b>189,240,716.1</b>
IV.	<b>Expenses:</b>			
	Cost of materials consumed	16	139,187,848.77	159,076,647.1
	Change In Inventories of Finished Good, Work In Progress	17	(1,964,114.00)	567,315.0
	Employee benefits expense	18	13,467,555.74	12,921,852.3
	Finance costs	19	4,050,287.82	3,720,617.4
	Depreciation and amortization expense	8	3,116,340.17	3,632,483.0
	Other expenses	20	8,445,279.65	7,204,011.3
	<b>Total expenses</b>		<b>166,303,198.15</b>	<b>187,122,926.3</b>
V.	<b>Profit before exceptional and extraordinary items and tax (III-IV)</b>		<b>1,938,276.04</b>	<b>2,117,789.8</b>
VI.	Exceptional items		-	-
VII.	<b>Profit before extraordinary items and tax (V - VI)</b>		<b>1,938,276.04</b>	<b>2,117,789.8</b>
VIII.	Extraordinary items		-	-
IX.	<b>Profit before tax (VII- VIII)</b>		<b>1,938,276.04</b>	<b>2,117,789.8</b>
X	Tax expense:			
	(1) Current tax		500,000.00	550,000.00
	(2) Deferred tax		-	-
	(3) Previous Year Tax		(138,337.00)	50,000.00
XI	<b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>		<b>1,576,613.04</b>	<b>1,517,789.8</b>
XII	Profit/(loss) from discontinuing operations		-	-
XIII	Tax expense of discontinuing operations/ Income Tax for Earlier Years		-	-
XIV	<b>Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)</b>		<b>-</b>	<b>-</b>
XV	<b>Profit (Loss) for the period (XI + XIV)</b>		<b>1,576,613.04</b>	<b>1,517,789.8</b>
XVI	Earnings per equity share:			
	(1) Basic		0.48	0.46
	(2) Diluted		0.48	0.46


FOR & ON BEHALF OF THE BOARD OF DIRECTOR

AS PER OUR SEPARATE REPORT OF EVEN DATE ATTACHED  
 FOR SINGH YUDHVEER & ASSOCIATES  
 CHARTERED ACCOUNTANTS

A VENUGOPAL  
**For Vilin Bio Med Ltd**  
  
 Managing Director  
 MG. DIRECTOR  
 DIN-01918868

ANVESH MOOLA  
  
 DIRECTOR  
 DIN-08659891



  
 YUDHVEER SINGH  
 PROPRIETOR  
 M. NO. 401054

PLACE: ROORKEE  
 DATE: 26-12-2020

**M/S VILIN BIO MED LIMITED**

**REGD. OFF:** H. NO. 6-61-1, 1<sup>ST</sup> FLOOR, SHILPI COMPLEX  
DILSUKHNAGAR, HYDERABAD, TELANGANA - 500035  
**WORKS:** KH. NO. 85, VILL. - MADHOPUR HAZRATPUR,  
ROORKEE-247667 (U.K.)

**Note: 1**

**SIGNIFICANT ACCOUNTING POLICIES:**

**I. Basis of preparation of financial statements**

The financial statements are prepared under the historical cost convention, in accordance with the Indian Generally Accepted Accounting Principles comprising the mandatory accounting standards issued by the Institute of Chartered Accountants of India and the provisions of the Companies Act, 2013 on accrual basis as adopted consistently by the company. All Assets and Liabilities have been classification as current or non-current as per the Company's normal operating cycle and other criteria set out in the revised schedule III of the Companies Act, 2013. For the purpose of current and non-current classification of assets and liabilities, the company has ascertained its operating cycle as 12 months for the purpose of current and non-current classification of assets and liabilities.

**II. System of Accounting**

- i) The company follows the mercantile system of accounting and recognizes income and expenditure on an accrual basis except in case of significant uncertainties.
- ii) Financial statements are based on historical cost. These costs are not adjusted to reflect the impact of changing value in the purchasing power of money.
- iii) Estimates and assumptions used in the preparation of the financial statements and disclosures are based upon management's evaluation of the relevant facts and circumstances as of the date of the financial Statements, which may differ from the actual results at a subsequent date.

**III. Use of Estimates**

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumption that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates. Adjustments as a result of differences between actual and estimates are prospectively made.

**IV. Revenue Recognition**

**Income**

The Company recognizes income on accrual basis. However, where the ultimate collection of the same lacks reasonable certainty, revenue recognition is postponed to the extent of uncertainty.

- i) Sales:  
Sales have been accounted for on dispatch of goods from the company's premises to the customers.

**V. Fixed Assets:**

Fixed Assets are stated at cost less accumulated depreciation. Cost includes all expenses incurred to bring the assets to its present location and condition.

**VI. Depreciation**

Depreciation (except on land which is not depreciated) is provided as per the provisions of The Companies Act 2013 which requires companies to compute the Depreciation in accordance with the Schedule II to the Companies Act which provides useful lives to compute the Depreciation. Depreciation on additions is pro-rata basis.



A. [Signature]  
Managing Director

[Signature]

## VII. Foreign Exchange Transactions

Transactions in foreign currencies are recorded at exchange rates prevailing on the date of the respective transactions. Current assets and current liabilities denominated in foreign currency are translated at the exchange rate prevailing at the date of balance sheet. The resulting difference between the rate prevailing on the date of transaction and on the date of settlement as also on translation of current assets and current liabilities (other than those related to fixed assets where it is adjusted to the cost of acquisition thereof) at the end of the year is recognized at the income or the expense as the case may be.

## VIII. Valuation of Inventories

Inventories are valued at cost or net realizable value whichever is lower. Cost of inventories comprise of all costs of purchase and other cost incurred in bringing the inventory to present location and condition.

- a) Raw Materials  
Raw materials are valued at cost or net realizable value at FIFO method.
- b) Finished Goods and Work-in-process  
Finished Goods are valued at cost or net realizable value at FIFO method and Work-in- Process is valued at cost.
- c) Stores, Spares and Packing Materials  
Stores, Spares and Packing Materials are valued at cost at FIFO method.

## IX. Employee Benefits

The company is not applying Accounting Standard -15. Employee Benefits for future are accounting on cash basis.

## X. Impairment of assets:

In the opinion of the company management there is no impairment to the assets to which accounting standard -28 "Impairment of assets" applied requiring any revenue recognition.

## XI. Income-Tax

Income Tax expenses comprise of the Current Income Tax, deferred tax charge or credit.

Current Tax is measured at the amount expected to be paid to the tax authorities in accordance with the provisions of Income Tax Act, 1961 as applicable to the financial year.

Deferred Taxes reflects the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier year.

Deferred tax is measured based on the tax laws enacted or substantively enacted at the balance sheet date. Deferred tax recognized only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized.

## XII. Borrowing Costs

The company is applying Accounting Standard-16.

As per AS-16, Financing/ Borrowing cost attributable to acquisition and / or construction of qualifying assets is to be capitalized as a part of the cost of such assets up to the date such assets are ready for their intended use. Other financing / Borrowing costs should be charged to profit & loss account.

## XIII. Provisions, Contingent Liabilities and Contingent Assets

A provision is recognized when the company has a present obligation as a result of past event, it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at the balance sheet date and adjusted to reflect the current best estimates. Contingent liabilities are not recognized but are disclosed in the notes. Contingent Assets are neither recognized nor disclosed in the financial statements.



**VILIN BIO-MED LIMITED**  
 REGD. OFF : H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR  
 HYDERABAD, TELANGANA - 500035  
 - WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667  
 DISTT - HARIDWAR, UTTARAKHAND

NOTES ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2020

**NOTE NO. 2**  
**SHARE CAPITAL:**

**(A) Authorised, Issued, Subscribed & Paid-up Share Capital:-**

PARTICULARS	AS AT 31st MARCH 2020 (IN RS.)	AS AT 31st MARCH 2019 (IN RS.)
<b>Authorised Share Capital</b> [33,00,000 Equity Shares of RS. 10/- Each]	33,000,000.00	33,000,000.00
<b>Issued, Subscribed and Paid-up Capital</b> [33,00,000 Equity Shares of RS. 10/- Each]	33,000,000.00	33,000,000.00
<b>TOTAL</b>	<b>33,000,000.00</b>	<b>33,000,000.00</b>

**(B) Reconciliation of the Number of Share Outstanding:-**

PARTICULARS	AS AT 31st MARCH 2020 NUMBER	AS AT 31st MARCH 2019 NUMBER
Equity Shares Outstanding at the beginning of the year	3,300,000	3,300,000
Add: Equity Shares allotted during the year	-	-
Equity shares outstanding at the end of the year	<b>3,300,000</b>	<b>3,300,000</b>

**(C) Shareholders Holding More than 5% Shares of the Company:-**

NAME OF SHAREHOLDERS	CLASS OF SHARES	AS AT 31st MARCH 2020		AS AT 31st MARCH 2019	
		NUMBER	%	NUMBER	%
(i) Akki Reddy Pradeep Reddy	Equity Shares	455,882	13.81	455,882	13.81
(ii) Merugu Ramesh	Equity Shares	389,706	11.81	389,706	11.81
(iii) Roopi Reddy Srikanth Reddy	Equity Shares	370,589	11.23	370,589	11.23
(iv) Merugu Vanitha	Equity Shares	270,294	8.19	270,294	8.19
(v) A. Venugopal	Equity Shares	262,118	7.94	262,118	7.94
(vi) Nalla Surender Reddy	Equity Shares	212,353	6.43	212,353	6.43
(vii) Akki Reddy Namratha Reddy	Equity Shares	204,118	6.19	204,118	6.19
(viii) B. Meghamala	Equity Shares	170,588	5.17	170,588	5.17

**Rights, Preferences and Restrictions attached to each class of Shares and Terms of redemption:-**

- i. The company has only one class of shares referred as equity shares. The equity share are having a par value of Rs. 10/- each. Every holder of equity share is entitled one vote per share in respect of all matters submitted to vote in the shareholders's meeting.
- ii. In the event of liquidation of the company, the holder of equity shares will be entitled to receive the remaining assets of the company after distribution of preferent amounts. The distribution will be in the portion of the number of equity shares held by the shareholders.

Note:- During last 5 years immediately preceding the balance sheet date, No equity share or preference shares has been issued pursuant to any contract without payment being received in cash. Further the company has neither allotted any share by way of bonus shares nor it had bought back any equity or preference share during aforesaid period of 5 Years.

For Vilin Bio Med Ltd  
 Managing Director

G  
 Tel



**VILIN BIO-MED LIMITED**  
**REGD. OFF :H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR**  
**HYDERABAD, TELANGANA - 500035**  
**WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667**  
**DISTT - HARIDWAR, UTTARAKHAND**  
**CIN :- U24230TG2005PLC046689**

NOTE ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2020

PARTICULARES	AS AT 1st APRIL 2019 (IN RS.)	ADDITIONS / CREATED DURING THE YEAR	Deductions During the Year	AS AT 31st MARCH 2020(IN RS.)
<b>NOTE NO - 3</b>				
<b>RESERVE &amp; SURPLUS</b>				
CAPITAL RESERVE ( CAPITAL INVESTMENT SUBSIDY)	2,255,567.00	-	-	2,255,567.00
<b>Total(A)</b>	2,255,567.00	-	-	2,255,567.00
SURPLUS AS PER PROFIT & LOSS ACCOUNT	35,535,929.45	1,576,613.04	-	37,112,542.49
<b>Total(B)</b>	35,535,929.45	1,576,613.04	-	37,112,542.49
<b>Total(A+B)</b>	37,791,496.45	1,576,613.04	-	39,368,109.49

For Vilin Bio Med Ltd.  
*A. V. V.*  
 Managing Director

*S. J.*



**VILIN BIO-MED LIMITED**  
 REGD. OFF : H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR  
 HYDERABAD, TELANGANA - 500035  
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667  
 DISTT - HARIDWAR, UTTARAKHAND

NOTES ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2020

PARTICULARS	AS AT 31st MARCH 2020 (IN RS.)	AS AT 31st MARCH 2019 (IN RS.)
<b>NOTE NO. -4</b>		
<b>SHORT-TERM BORROWINGS</b>		
<b>SECURED LOAN:-</b>		
<b>Loans From Bank</b>		
P.N.B. Ram Nagar, Roorkee CC- A/c-16831	45,341,186.00	30,271,069.00
[Secured against Hypothecation of Stock and Book Debts]		
<b>TOTAL</b>	<b>45,341,186.00</b>	<b>30,271,069.00</b>

For Vilin Bio Med Ltd

*A. J. J.*  
 Managing Director

*C.L.*



M/S VILIN BIOMED LIMITED  
 REGD OFF : H.NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX  
 DILSUKHNAGAR, HYDERABAD, ANDHRA PRADESH - 500035  
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667  
 DISTT - HARIDWAR, UTTARAKHAND

STATEMENT OF FIXED (TANGIBLE) ASSETS ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2020

Note No. -8

PARTICULARS	GROSS BLOCK				DEPRECIATION			NET BLOCK	
	BALANCE AS ON 01.04.2019	ADDITIONS UP TO 30.09.2019	ADDITIONS AFTER 30.09.2019	TOTAL AS ON 31.03.2020	BALANCE AS ON 01.04.2019	FOR THE YEAR	TOTAL AS ON 31.03.2020	BALANCE AS ON 31.03.2020	BALANCE AS ON 31.03.2019
LAND	2,115,400.00	-	-	2,115,400.00	-	-	-	2,115,400.00	2,115,400.00
BUILDING	34,899,407.00	-	-	34,899,407.00	22,246,666.68	1,189,889.35	23,436,556.03	11,462,850.97	12,652,740.32
FURNITURE & FIXTURE	1,596,291.00	-	-	1,596,291.00	1,121,106.74	122,960.25	1,244,066.99	352,224.01	475,184.26
PLANT & MACHINERY	52,700,963.00	241,916	-	52,942,878.54	43,963,178.72	1,773,124.91	45,736,303.64	7,206,574.90	8,737,784.28
COMPUTERS	460,746.00	-	-	460,746.00	443,665.00	-	443,665.00	17,081.00	17,081.00
OFFICE EQUIPMENT	367,657.60	-	-	367,657.60	306,627.04	25,224.36	331,851.40	35,806.20	61,030.56
VEHICLE	1,170,875.00	-	-	1,170,875.00	1,095,373.19	5,141.29	1,100,514.48	70,360.52	75,501.81
<b>TOTAL (Rs.)</b>	<b>93,311,339.60</b>	<b>241,915.54</b>	<b>-</b>	<b>93,553,255.14</b>	<b>69,176,617.38</b>	<b>3,116,340.17</b>	<b>72,292,957.54</b>	<b>21,260,297.60</b>	<b>24,134,722.72</b>

For Vilin Bio Med  
*A. Urf*  
 Managing Director



**VILIN BIO-MED LIMITED**  
 REGD. OFF : H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR  
 HYDERABAD, TELANGANA - 500035  
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667  
 DISTT - HARIDWAR, UTTARAKHAND

NOTES ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2020

PARTICULARS	AS AT 31st MARCH 2020 (IN RS.)	AS AT 31st MARCH 2019 (IN RS.)
<b>NOTE NO. -5</b>		
<b>TRADE PAYABLE</b> For Purchases & Others	18,605,552.25	10,190,916.83
<b>TOTAL</b>	<b>18,605,552.25</b>	<b>10,190,916.83</b>
<b>NOTE NO. -6</b>		
<b>OTHER CURRENT LIABILITIES</b> Expenses Payable	2,478,665.00	5,559,477.37
<b>TOTAL</b>	<b>2,478,665.00</b>	<b>5,559,477.37</b>
<b>NOTE NO. -7</b>		
<b>SHORT TERM PROVISION</b> Provision For Income Tax ( A.Y. 2019-20) Provision For Audit Fee	500,000.00 150,000.00	550,000.00 147,500.00
<b>TOTAL</b>	<b>650,000.00</b>	<b>697,500.00</b>

For Vilin BioMed Ltd  
 A. [Signature]  
 Managing Director


[Handwritten initials]



**VILIN BIO-MED LIMITED**  
**REGD. OFF :H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR**  
**HYDERABAD, TELANGANA - 500035**  
**WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667**  
**DISTT - HARIDWAR, UTTARAKHAND**

**NOTES ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2020**

PARTICULARS	AS AT 31st MARCH 2020 (IN RS.)	AS AT 31st MARCH 2019 (IN RS.)
<b><u>NOTE NO. -9</u></b>		
<b><u>LONG TERM LOAN AND ADVANCE</u></b>		
Earnest Money & Security	485,213.00	485,213.00
<b>TOTAL</b>	<b>485,213.00</b>	<b>485,213.00</b>
<b><u>NOTE NO. -10</u></b>		
<b><u>INVENTORIES</u></b>		
<b>As taken value certified by the management:</b>		
Raw Materials & Packing Materials	18,561,733.00	19,462,654.9
Semi Finished Good	845,655.00	205,425.0
Finished Good	1,688,590.00	364,706.0
<b>TOTAL</b>	<b>21,095,978.00</b>	<b>20,032,785.9</b>
<b><u>NOTE NO. -11</u></b>		
<b><u>TRADE RECEIVABLE</u></b>		
Trade Receivable	72,693,180.08	61,242,840.8
<b>TOTAL</b>	<b>72,693,180.08</b>	<b>61,242,840.8</b>
<b><u>NOTE NO. -12</u></b>		
<b><u>CASH AND BANK BALANCES</u></b>		
Cash In Hand	666,207.84	395,880.0
<b>TOTAL</b>	<b>666,207.84</b>	<b>395,880.0</b>
<b><u>NOTE NO. -13</u></b>		
<b><u>SHORT TERM LOAN &amp; ADVANCES</u></b>		
Sundry Advances	8,179,504.20	1,060,000.0
GST ITC	15,679,290.73	10,776,176.7
<b>TOTAL</b>	<b>23,858,794.93</b>	<b>11,836,176.7</b>

For Vilin Bio Med Ltd  
  
**Managing Director**



**VILIN BIO-MED LIMITED**  
 REGD. OFF : H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR  
 HYDERABAD, TELANGANA - 500035  
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667  
 DISTT - HARIDWAR, UTTARAKHAND

NOTES ANNEXED TO AND FORMING PART OF PROFIT AS AT 31ST MARCH 2020

PARTICULARS	AS AT 31st MARCH 2020 (IN RS.)	AS AT 31st MARCH 2019 (IN RS.)
<b>NOTE NO. -14</b>		
<b>REVENUE FROM OPERATIONS</b>		
Net Sales	168,129,474.19	189,240,716.1
<b>TOTAL</b>	<b>168,129,474.19</b>	<b>189,240,716.1</b>
<b>NOTE NO. -15</b>		
<b>OTHER INCOME</b>		
Other Income	112,000.00	
<b>Total</b>	<b>112,000.00</b>	
<b>NOTE NO. -16</b>		
<b>COST OF MATERIAL CONSUMED</b>		
Opening Stock	19,462,654.92	19,677,164
Add: Purchase Net	138,286,926.85	158,862,138
Less: Closing Stock	18,561,733.00	19,462,654
<b>TOTAL</b>	<b>139,187,848.77</b>	<b>159,076,547</b>
<b>NOTE NO. -17</b>		
<b>CHANGES IN INVENTORY OF FINISHED GOOD WORK IN PROGRESS AND STOCK IN TRADE</b>		
Increase/ Decrease in Stock		
<b>[A] Closing Stock</b>		
Work In Progress	845,655.00	205,4
Finished Good	1,688,590.00	364,7
<b>TOTAL</b>	<b>2,534,245.00</b>	<b>570,1</b>
<b>[B] Opening Stock</b>		
Work In Progress	205,425.00	528,4
Finished Good	364,706.00	609,0
<b>TOTAL</b>	<b>570,131.00</b>	<b>1,137,4</b>
<b>Net Increase/ (Decrease) [A]-[B]</b>	<b>(1,964,114.00)</b>	<b>567,3</b>

For Vilin Bio Med Ltd  
 A- [Signature]  
 Managing Director



**VILIN BIO-MED LIMITED**  
 REGD. OFF : H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR  
 HYDERABAD, TELANGANA - 500035  
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667  
 DISTT - HARIDWAR, UTTARAKHAND

NOTES ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2020

PARTICULARS	AS AT 31st MARCH 2020 (IN RS.)	AS AT 31st MARCH 2019 (IN RS.)
<b>NOTE NO. -18</b>		
<b>EMPLOYEE BENEFITS EXPENSES</b>		
Salary & Wages	11,342,890.00	11,090,231.00
Directors Remuneration	1,500,000.00	1,200,000.00
Staff Welfare/ Labour Uniform	462,224.00	475,059.00
EPF Administration Charges	10,398.00	9,041.00
EPF Contribution	105,439.00	73,229.00
ESIC Contribution	46,604.74	74,292.37
<b>TOTAL</b>	<b>13,467,555.74</b>	<b>12,921,852.37</b>
<b>NOTE NO. -19</b>		
<b>FINANCE COST</b>		
Interest On CC Limit	3,801,279.00	3,554,762.00
Bank Charges	249,008.82	165,855.41
<b>TOTAL</b>	<b>4,050,287.82</b>	<b>3,720,617.41</b>

For Vilin Bio Med Ltd  
 A [Signature]  
 Managing Director

[Signature]



**VILIN BIO-MED LIMITED**  
**REGD. OFF :H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR**  
**HYDERABAD, TELANGANA - 500035**  
**WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667**  
**DISTT - HARIDWAR, UTTARAKHAND**

**NOTES ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2020**

PARTICULARS	AS AT 31st MARCH 2020 (IN RS.)	AS AT 31st MARCH 2019 (IN RS.)
<b>NOTE NO. -20</b>		
<b>OTHER EXPENSES</b>		
<b>Manufacturing Exp.:-</b>		
Freight Inward	212,624.87	229,361.14
Consumable Stores	33,130.00	157,146.00
Generator Runing & Maintenance Expenses	617,964.00	673,588.00
Lab Testing Charges	231,290.00	182,411.25
Drug Office Expenses	129,000.00	20,050.00
Power Expenses	1,597,908.11	1,590,955.00
<b>Others:-</b>		
Insurance Charges	81,238.60	98,718.73
Miscellaneous Expenses	479,914.80	67,626.00
Printing & Stationary	37,500.00	20,520.00
Office & General Expenses	379,020.20	331,591.00
Postage & Telegram	5,778.00	6,560.00
Professional Fee Expenses	372,000.00	165,000.00
Repairs to Plant & Machinery	406,971.96	351,855.00
Repair & Maintenance Other	356,255.00	512,474.00
Telephone Expenses	53,442.14	65,260.62
Travelling & Conveyance Expenses (Including Director's Travelling)	403,703.00	274,286.80
Security Expenses	642,424.00	442,057.00
Vehicle Running & Maintenance	194,143.00	180,898.00
Rate Diffrance/ Rebate & Discount	1,926,096.00	1,686,152.80
Festival Expenses	99,812.00	-
Audit Fee	150,000.00	147,500.00
Business Promotion	35,000.00	-
Short & Excess/ Recovery	63.97	-
<b>TOTAL</b>	<b>8,445,279.65</b>	<b>7,204,011.34</b>

For Vilin Bio Med Ltd  
A. [Signature]  
Managing Director

G  
[Signature]

